Feed PLX
PL

Protalix BioTherapeutics, Inc.

PLX · AMEX

$2.81 +1.81% (+$0.05)
1M +14.11%
Market Cap $222.0M
P/E Ratio 11.72x
Div. Yield -
ROE 31.61%

Bulios Fair Price

$1.46

48.0% downside

Trenutna cena

$2.81

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica PLX trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
4/9
Valuation
75 /100
Cheap
EV/EBITDA 7.75x
P/S 2.75x
P/B 3.11x
Growth
37 /100
Stable
Rev. growth 3.45%
FCF growth N/A
Book val. growth N/A
Profitability
89 /100
Strong
Net margin 23.50%
Op. margin 28.89%
FCF margin 9.51%
Quality
94 /100
Excellent
ROE 31.61%
ROA 17.17%
Asset turnover 0.73x
Debt
100 /100
Low
Current ratio 2.94x
Int. coverage 19.77x
Net debt/EBITDA -0.69x
Stability
11 /100
Unstable
Rev. volatility 28.65%
EPS volatility 231.92%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o PLX
Online

O podjetju

Protalix BioTherapeutics, Inc. (PLX) is a biotechnology company based in Israel, specializing in the development and production of biotechnology-based drugs. With a primary focus on research and development of drugs for rare diseases and genetic disorders, Protalix BioTherapeutics is a recognized player in the field of biologic therapeutics. The company is an innovative leader in the field of recombinant proteins and utilizes plant cell technology to produce drugs with higher efficacy and lower costs. Protalix BioTherapeutics aims to collaborate with pharmaceutical companies and biotechnology partners worldwide to bring new drugs to market and improve healthcare for patients suffering from rare diseases. Protalix BioTherapeutics, Inc. (PLX) shares could be suitable for investors seeking investment opportunities in biotechnology and drugs for rare diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Dror Bashan

Employees

226

Headquarters

Hackensack

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

51d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.